EMT markers gene expression in BPIFB2 overexpressed gastric cancer cell lines

Abstract

predict the possibility of advanced gastric cancer patients to receive third-line chemotherapy, based on their baseline characteristics. Methods: We retrospectively collected baseline characteristics and treatment data of 271 patients with unresected advanced gastric cancer who started chemotherapy between January 2006 and June 2017 in Kurashiki Central Hospital. A median age was 68 years, and 190 patients were male. The relationship between patients' characteristics and delivery rate to third-line chemotherapy were investigated. Results: Among the 271 patients, 71 patients (26.2%) received third-line chemotherapy. On univariate analysis, delivery rate to third-line chemotherapy were significantly related to patients' Eastern Cooperative Oncology Group (ECOG) performance status (PS), cancer histology and several laboratory test results at the baseline. Multivariate analysis revealed that PS 0 and serum CRP levels 0.6 mg/dl were independent predictive factors for delivery to third-line chemotherapy; adjusted odds ratio (95% confidence interval) was 4.14 (2.11-8.14) and 2.47 (1 .20-5.11), respectively.

A 6-Gene Risk Signature Predicts Survival of Glioblastoma Multiforme

“…Though few studies have investigated roles of BPIFB2 , XIRP2 and NELL1 in GBM, all the three genes may have potential roles in other cancers. BPIFB2 has been reported to be overexpressed in gastric cancer, which may result in expression alteration of epithelial-mesenchymal transition (EMT) markers [23], and XIRP2 has been shown to be frequently mutated in lung adenocarcinoma [24]. As a gene encoding a secreted protein regulating skeletal ossification [25], NELL1 has also been proposed to be a tumor suppressor gene in colon cancers [26].…”